| Friday, November 20th 2020 Recording of TreatER webcast seminar – World’s first clinical trial with CDNF: Aiming for a breakthrough in Parkinson’s Read More | Tuesday, September 15th 2020 Recording of webinar – CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months Read More | Friday, September 11th 2020 Registration open for TreatER webcast seminar on 18 November 2020 – World’s first clinical trial with CDNF: Aiming for a breakthrough in Parkinson’s Read More | Thursday, August 27th 2020 Renishaw announces completion of clinical trial extension study, using its innovative drug delivery system in the investigation of CDNF as a treatment for Parkinson’s disease Read More | Thursday, August 27th 2020 Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months Read More | Wednesday, April 15th 2020 Initial clinical data shows promising signals of the biological activity of CDNF in Parkinson’s disease Read More | Thursday, March 5th 2020 CDNF early data show biological promise Read More | Tuesday, February 25th 2020 Renishaw announces completion of the main part of a multi-centre clinical trial Read More | Tuesday, February 25th 2020 Herantis Pharma Plc announces topline results of Phase 1-2 CDNF trial Read More | Thursday, December 19th 2019 Herantis Pharma Plc completes patient treatments in main study of Phase 1-2 CDNF trial in Parkinson’s disease Read More
